The United States Judicial Panel on Multi-District Litigation (MDL) recently convened to determine whether the cases, known as IN RE: XARELTO (RIVAROXABAN)
PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.
The Judicial Panel granted MDL status and signed a Transfer Order on December 12, 2014. The cases will be consolidated and transferred to the Eastern District of Louisiana and presided over by the Honorable Eldon E. Fallon. The Judicial Panel decided the Eastern District of Louisiana was appropriate given the number of filings potential tag-along cases in that district and the fact that Judge Fallon is an experienced transferee judge with a willingness and ability to manage the litigation efficiently.
If you feel you have experienced any side-effects from taking Xarelto, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Xarelto manufacturers.